Browse the evidence

Tirzepatide manages blood sugar levels and enhances weight loss more than GLP-1 receptor agonists.

Tirzepatide may be more effective than GLP-1 receptor agonists for patients needing blood sugar and weight management.

Continuing GLP-1 or GIP agonists before upper endoscopy increases the risk of clinically significant residual gastric volume (RGV).

Practitioners should consider holding GLP-1 or GIP agonists prior to upper endoscopy to reduce the risk of RGV.

Holding one dose of GLP-1 or GIP agonists significantly reduces the risk of clinically significant RGV.

Holding the medication prior to the procedure is advisable to minimize RGV risk.

Clear liquids the day prior to the procedure may mitigate the risk of clinically significant RGV regardless of GLP-1/GIP use.

Encouraging clear liquids before procedures may help reduce RGV risk.

Tirzepatide is available for the treatment of hyperglycemia in patients with type 2 diabetes.

Practitioners can consider tirzepatide as a treatment option for managing hyperglycemia in type 2 diabetes patients.

Tirzepatide is a novel treatment option for Type 2 diabetes mellitus (T2DM) that may benefit individuals with cardiovascular disease or heart failure.

Tirzepatide may be considered for T2DM patients with cardiovascular concerns.

Semaglutide improved glycemic control, with HbA1c decreasing by 0.4 ± 0.6%.

Semaglutide may be a beneficial treatment for improving glycemic control in patients with type 1 diabetes.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 29% lower risk of major adverse cardiovascular events (MACE).

Targeting GIP receptor pathways may significantly reduce cardiovascular event risk.

1 kg/m² lower BMI via the GIP/GIPR score is associated with 43% lower risk of heart failure.

Targeting GIP receptor pathways may significantly reduce heart failure risk.

Menopause is associated with weight gain and a predisposition to obesity in women.

Practitioners should be aware of the increased risk of weight gain in menopausal women.

Women begin to lose lean mass during menopause, leading to an increase in fat mass.

Practitioners should monitor body composition changes in menopausal women.

Targeted antiobesity medications (AOM) have demonstrated significant weight loss and improved quality of life in patients with specific genetic obesity disorders.

Practitioners should consider targeted AOMs for patients with genetic obesity disorders to improve weight management and quality of life.

Nontargeted AOMs can achieve similar benefits in patients with specific genetic obesity disorders compared to common multifactorial obesity.

Practitioners may consider nontargeted AOMs as an alternative for managing obesity in patients with genetic disorders.

GLP-1RA-induced weight loss would lead to a marked decrease in cancer cases over 10 years in adults.

Implementing GLP-1RA treatments could significantly reduce cancer incidence in obese populations.

If GLP-1RAs were made available for all people with obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 21,443.

Wider access to GLP-1RAs could lead to significant reductions in cancer cases among obese individuals.

GLP-1 receptor agonists promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity.

GLP-1 receptor agonists can be considered for managing type 2 diabetes and obesity in clinical practice.

GLP-1 receptor agonists reduce cardiovascular risk and slow progression to renal failure in persons at high risk and those with type 2 diabetes.

Consider GLP-1 receptor agonists for patients at high risk of cardiovascular issues or renal failure.

Tirzepatide has potential impacts on diabetes, obesity, NASH, and cardiovascular risks.

Tirzepatide may be beneficial for patients with diabetes and associated comorbidities.

Reinitiating semaglutide at the target dose after a treatment gap can lead to adverse effects.

Caution is advised when reinitiating GLP-1 therapy after a gap, especially at target doses.

Therapy lapses with GLP-1 receptor agonists may be prevented by a multi-modal approach.

Implementing a multi-modal strategy can help maintain GLP-1 therapy adherence.

HEC-CG115 reduced fasting blood glucose and glycated haemoglobin levels similar to those after semaglutide.

HEC-CG115 may provide effective glycaemic control for patients with type 2 diabetes.

Tirzepatide achieved MASH resolution with no worsening of fibrosis in a significantly higher percentage of patients than placebo.

Tirzepatide may be a promising treatment option for patients with MASH, potentially improving liver health.

More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.

Tirzepatide may help improve liver fibrosis in patients with MASH.

Tirzepatide has been approved for the treatment of adults with type 2 diabetes who are overweight/obese or have weight-related comorbidities.

Tirzepatide is a viable treatment option for managing type 2 diabetes in specific patient populations.